99.99th Percentile IQ Embryo Selected. What does it all mean? @JonathanAnomaly explains how polygenic embryo selection is moving from science fiction into reality. And why the biggest barrier may no longer be technology, but culture. 00:00 - Viral IQ Embryo & Eugenics 07:10 - PGT Adoption 11:20 - Will Governments Ban This? 15:30 - Fertility Decline & Genetic Selection 21:30 - How Accurate? 28:50 - The Heritability Ceiling 35:20 - Autism, Neurodivergence 37:30 - A Genetic Vaccine 42:40 - PGT Skepticism 48:05 - Dangers of Pleiotropy 55:05 - The Adoption Curve 58:30 - Future of IVF 1:06:00 - Pronatalists & The Future 1:11:10 - Embryo Selection vs Editing 1:17:30 - Building Better Humans

if you catch yourself going down rabbit holes about gene editing, personalized health, human 2.0, bionic limbs, gene therapies, neurotech, exoskeletons, jet suits, cellular reprogramming, longevity drugs, AI-designed therapeutics, rapamycin, peptides, senolytics, NAD boosters, mitochondrial health, enhanced humans, psychedelics, embryo selection, germline editing, biological age diagnostics, BCIs, artificial wombs, epigenetic reprogramming, and not dying, etc if you're following, building or funding this account is for you, DMs are open too bio/acc.

hot take: 90% of biotech startups aren't fundable not because the science doesn't work, because they're building a product we're looking for founders building the infrastructure that makes thousands of products possible - autonomous wet labs - peptide quality infrastructure - AI-native biology tooling - biological age diagnostics - clinical trial infrastructure - non-invasive BCIs - and/or adjacent biotech the products get funded easily. the infrastructure underneath them almost never does. that's the gap we're closing let's talk, what are you building?

your longevity protocol: board-certified physician, quarterly biomarkers, evidence-based interventions my longevity protocol: "this peptide has a really convincing substack"

BIG BIG NEWS: Anthropic just announced it's developing drugs of its own just after launching Claude Science, an AI workbench connected to 60 scientific tools and databases, capable of running single-cell RNA sequencing and CRISPR design autonomously now they're not just building the tool. they're using it themselves to run an internal drug discovery lab targeting neglected diseases the traditional pharma industry has written off as not commercially attractive Anthropic's head of life sciences said it plainly: "there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs" this is on top of their $400M acquisition of Coefficient Bio in April, which quietly gave them the life sciences expertise to make this move Isomorphic Labs, Recursion, Insilico all entered this race with AI-first drug discovery now the frontier AI labs are not just tooling up pharma they are becoming pharma the acceleration of biology can never be doubted ever again

- longevity biotech founder - turned a garage into a drug discovery company - accidentally started a company while trying to cure their own disease - thinks proteins are the new source code - has Claude as a cofounder - thinks biology should compile - GitHub before a patent - has a robot running experiments while they sleep - spends more time prompting than pipetting - thinks the next biotech unicorn starts with a laptop there are like 500 of these on twitter I wanna fund the most unhinged ones.

in case you missed the longevity biotech acceleration in the first half of 2026 these signals will make you optimistic: - FDA cleared Life Biosciences' ER-100, the first cellular rejuvenation trial in human history, using partial epigenetic reprogramming - China reversed type 2 diabetes in a patient using stem-cell-derived insulin cells. the patient stopped insulin completely - peptides broke the floodgates. reta hit 30% bodyweight loss in Phase 3. 65% of patients no longer clinically obese. and 14 of 19 banned compounds came back to legal compounding - germline editing hit 100% efficiency with zero chromosomal abnormalities. genetic diseases are being engineered out of the lineage - Conception generated the first early human egg cells from stem cells. reproductive biology just became engineerable - $3.74B raised across 49 longevity biotech deals in Q1 alone, 56% ahead of Q1 2025. biotech exits hit $13.3B, the highest since 2021 - Kailera Therapeutics IPO'd at $625M, the largest biotech IPO ever - daraxonrasib nearly doubled survival in pancreatic cancer. RAS undruggable for 40 years. they drugged it. 42 second standing ovation at ASCO - Life Biosciences dosed the first human with the therapy designed to reverse cellular aging - Isomorphic Labs raised $2.1B. NewLimit raised $435M. Retro Biosciences raised at $1.8B valuation. the capital has decided - biopharma M&A hit $84B in four months. AbbVie, GSK, Gilead, Lilly all moving simultaneously we've never been more bullish if you're building on the longevity biotech infrastructure layer, we want to fund you- comment or DM bio/acc

The first-order effect of longevity biotech won't be living forever. It'll be making "dying of old age" feel increasingly like a technical failure rather than a fact of life.

The most important fertility breakthrough of the year just dropped. Conception generated the first early human egg cells derived from stem cells. - a blood sample - reprogrammed into stem cells - then guided into miniature human ovaries that began producing early-stage egg cells Healthy mice have already been born using the same underlying approach in animals. If this translates to humans, the implications are enormous: - fertility no longer constrained by the number of eggs you're born with - simpler, more scalable IVF - entirely new ways to study infertility and reproductive aging - better models for understanding menopause - a new platform for reproductive medicine for most of human history, reproductive biology has been something we accepted. we're starting to engineer it. biological age diagnostics, reproductive biology, epigenetic reprogramming, the picks and shovels behind breakthroughs like this- that's what Superhuman Fund is here for, DM. bio/acc

WTF

you don't understand how dangerous garage biotech is about to become Anthropic casually launched Claude for Science A research workspace with: - 60 scientific databases - artifact tracing to source papers - on-demand computational environments People were already doing ridiculous things before this. - designing drug candidates from home - sequencing genomes on kitchen tables - building personalized cancer vaccines - running liquid-handling robots with Claude Code Every new AI capability compounds on top of the last one. The minimum viable biotech startup just keeps getting smaller. bio/acc

I think we're heavily underestimating whats coming A pronatalist future

we are scouting for the most unhinged biotech builders the ones who: - turned a kitchen table into a genome sequencing lab, or a garage into a drug discovery pipeline - can tell you exactly what's in a peptide vial when nobody else can - accidentally started a company while trying to cure their own disease - are building the boring infrastructure nobody else wants to fund because the drugs get all the attention If your startup belongs in this timeline, we should talk

we're funding the people building the infrastructure that makes breakthroughs like this possible. if you/someone you know is building anywhere on this layer, comment here.

Meta is making brain surgery optional Their new Brain2Qwerty model decoded full sentences directly from brain activity No implant. No electrodes. Their non-invasive MEG headset and LLM are purely trained on neural signals - 61% average word accuracy - 78% for the best participant - More than half the decoded sentences had one word error or less 18 months ago this was sci-fi Now they're open-sourcing the training code and dataset, and we can't be more bullish BCIs, biological diagnostics, programmable biology, AI for drug discovery, the boring picks and shovels everyone ignores if you're building anywhere on this infrastructure layer, Superhuman Fund is actively deploying capital- come find us bio/acc

the rabbit hole gets deeper every week Nvidia and Eli Lilly are building a $1B lab in the mighty San Francisco for AI drug discovery Lilly's CEO just revealed the actual moat "some scale tech-bio players are just training on public data, but there's only 4,000 ever approved drugs. Lilly alone has more than 3 million failed drugs" lilly 3 million data points x nvidia compute = bio/acc

we went from needing a pharma lab and a team of 20 to design a new drug candidate, to one guy in a garage doing it with Claude Code PAC-832. a novel Alzheimer's drug candidate. designed, synthesized, and tested by a single person. frontier AI. desktop sequencers. open-source biology. cloud labs. the tools that used to gatekeep who gets to work on hard problems are disappearing this is becoming the default way biotech gets built if you're building where AI meets biology, Superhuman Fund is probably aligned with your mission let's talk